TG Therapeutics Expects Briumvi Revenue of $825M to $850M in FY26
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: stocktwits
- Market Opportunity: CEO Michael S. Weiss stated that Briumvi has a 'multi-billion dollar opportunity,' with U.S. revenue expected to reach between $825 million and $850 million in FY26, representing a significant portion of the company's overall revenue.
- Revenue Expectations: The company anticipates total revenue of approximately $616 million for FY25, including $594 million from Briumvi sales in the U.S., exceeding Wall Street's estimate of $606.03 million, indicating robust market demand.
- Product Development: TG Therapeutics is developing a subcutaneous formulation of Briumvi to enhance administration ease, which, if approved, is expected to drive revenue acceleration in the short to mid-term and strengthen market positioning.
- Stock Market Reaction: Following the positive revenue outlook, TG Therapeutics shares rallied 7% in after-hours trading, reflecting strong investor confidence in the company's growth potential.
Analyst Views on TGTX
Wall Street analysts forecast TGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TGTX is 45.00 USD with a low forecast of 11.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 27.720
Low
11.00
Averages
45.00
High
60.00
Current: 27.720
Low
11.00
Averages
45.00
High
60.00
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
